Pharmaceuticals

AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025

TAIPEI, Oct. 13, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle...

2025-10-13 16:03 1227

Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

* Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies * Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve qu...

2025-10-13 14:26 1078

Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from bothChina's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). * EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is devel...

2025-10-13 08:47 1377

Reach Surgical's OMNIBOT Performs First Urology Robotic Telesurgeries in Latin America

Advancing regional collaboration and surgeon training in remote robotic-assisted surgery SINGAPORE, Oct. 13, 2025 /PRNewswire/ -- Reach Surgical, the Surgical Solutions division of Genesis MedTech, has facilitated the completion of two robotic telesurgeries using its OMNIBOT robotic-assisted sys...

2025-10-13 08:00 1230

Health in Your Hands? Asia's Top Health Experts Say 'Yes' and Reveal How

* Over 100 healthcare leaders from 11 countries/regions convene at APSMI Summit to advance consumer-led self-care in healthcare. * The Summit highlights the importance of empowering individuals with knowledge and tools to support resilient health systems. BALI, Indonesia, Oct. 10, 2025 /PRNew...

2025-10-10 14:43 1389

IHH Healthcare launches Global Incubator to fuel game-changing innovation

By enabling early-stage start-ups to bring breakthrough ideas to life, IHH is catalysing next-level care and driving lasting impact across the healthcare ecosystem. "Through this Global Incubator Programme, we are expanding our innovation drive to support early-stage healthcare innovators, empow...

2025-10-10 13:09 1313

Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission

* The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission * World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperati...

2025-10-09 20:50 1791

Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87

HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement wit...

2025-10-09 17:27 1374

Herbalgy, the Pain Management Expert, Partners with Heroes in White to Champion a "Pain-Relieving Serenity" Lifestyle

Bringing the Wisdom of Traditional Chinese Medicine into Modern Living HONG KONG, Oct. 9, 2025 /PRNewswire/ -- Following the phenomenal success of TVB's widely acclaimed TV dramaHeroes in White—the top-rated series of 2025 with an audience of over 1.57 million and a rating of 24.2 points—Herbalgy...

2025-10-09 14:18 1184

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted acrossAsia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the large...

2025-10-09 13:10 1355

New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific

* 32 million people in Asia-Pacific live with heart failure, and this number is rising fast. * New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. * Urgent call for early diagnosis, digital and community-based care, and sustainable financing t...

2025-10-08 09:00 1688

Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025

* Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 2025 1-3 * MSA is a rare, rapidly progressing, neurodegenerative disease...

2025-10-02 16:41 1561

Major Health Management Wins the 2025 Health Brand Awards - Excellence Award in Health Technology (Health Examination Platform): 38 Years of Quality Commitment, Transforming into a Leading Health Technology Pioneer

TAIPEI, Oct. 1, 2025 /PRNewswire/ -- Taiwan's leading health management brand,  Major Health Management, has been honored with the Excellence Award in Health Technology – Health Examination Platform at the 2025 Health Brand Awards. This award is a highly regarded annual recognition in the health i...

2025-10-01 14:51 1920

Telix Announces Record-Breaking Presence at EANM 2025

MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (E...

2025-10-01 13:57 1853

Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol

* Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living inSingapore. * Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve blood cholesterol management. [1] * Beat the Blo...

2025-09-30 10:00 1075

Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams

New IBD research shows that, even during clinical remission, people living with Crohn's diseasecontinue to experience greater work impairment than the general population The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endo...

2025-09-30 10:00 1927

Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences

* HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("...

2025-09-29 20:48 1133

Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital

LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition...

2025-09-29 12:58 1628

Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Surabaya A Celebration of Culture, Cuisine, Travel, and Healthcare Excellence

SURABAYA, Indonesia, Sept. 26, 2025 /PRNewswire/ -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration ofMalaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Su...

2025-09-26 09:45 2729

ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT

Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 25, 2025 /PRNewswire/ -- Advancion Corporation ("Advancion" or "Company"), a global leader in life science buffers and proprietary specialty ingre...

2025-09-25 02:40 1535
1 ... 891011121314 ... 187

Week's Top Stories